This is an editorial discussion of published research. It is not a treatment plan.
When the FDA advisory panel voted on tirzepatide compounding in late 2024, it didn't just shift the regulatory ground under one molecule. It forced the entire peptide supply chain, from bulk API importers to 503A pharmacies, to recalculate risk. Suddenly, a question that had been simmering in researcher forums and compounding networks became urgent: if tirzepatide's compounding pathway narrows, does AOD-9604 offer a safer, more defensible alternative? The answer isn't straightforward. It lives in the gap between regulatory precedent, adverse-event data, and the practical realities of lyophilized peptide production.
This sub-niche covers the intersection of metabolic peptide research and compounding regulation. It focuses on two compounds with very different mechanisms, AOD-9604, a fragment of human growth hormone, and tirzepatide, a dual GIP/GLP-1 receptor agonist, and asks which one carries less liability for compounding pharmacies in the current climate. The key compounds in this area include tirzepatide and AOD-9604, but also retatrutide, a triple agonist still in trials, hexarelin, a growth hormone secretagogue sometimes discussed alongside AOD-9604, and research peptides like MOTS-c and CJC-1295 that orbit the same metabolic research community.
The research consensus, if you can call it that, is lopsided. Tirzepatide has the weight of large phase 3 trials and a 2022 review (Frias 2022) showing mean weight loss of up to 22.5% over 72 weeks. AOD-9604 has a 2019 trial (Stier 2019) demonstrating modest fat loss in obese mice, and a handful of human studies from the early 2000s that never progressed beyond phase 2. The active research is almost entirely on the tirzepatide side, with ongoing studies exploring cardiovascular outcomes and sleep apnea. AOD-9604 research has stalled, with most citations coming from compounding pharmacies themselves or from anti-doping bodies flagging it as a substance of interest.
Where the gaps are is exactly where the compounding safety debate gets interesting. There is no published head-to-head safety comparison of compounded AOD-9604 versus compounded tirzepatide. There is no systematic review of adverse events from compounded AOD-9604. And there is no FDA guidance specific to AOD-9604 compounding, leaving pharmacies to interpret the law through the lens of tirzepatide enforcement actions.
The FDA panel vote didn't ban tirzepatide compounding outright. It recommended that tirzepatide be added to the list of drug products that present demonstrable difficulties for compounding, a category that includes most biologics and complex peptides. The practical effect, if the FDA adopts the recommendation, would be to push tirzepatide compounding into a legal gray zone where 503B outsourcing facilities might still operate but 503A pharmacies would face significant risk. A 2023 warning letter to a Florida compounder (FDA 2023) cited sterility failures in tirzepatide vials, and a 2024 analysis of compounded semaglutide (Jackson 2024) found that 22% of samples tested below 90% of labeled potency. These data points are now being used to argue that the safety risk of compounded tirzepatide is unacceptably high.
AOD-9604, by contrast, has no such enforcement history. It is not on any FDA shortage list, and it is not a biologic. It is a 16-amino-acid peptide fragment that can be synthesized with relative simplicity. A 2018 stability study (Patel 2018) showed that lyophilized AOD-9604 remains stable for 24 months at 4°C, which is longer than many compounded tirzepatide preparations. The cost difference is also stark. Compounded tirzepatide runs around $200 to $400 a month depending on dose, while AOD-9604 is often priced at $48 per vial in research settings. For compounding pharmacies, the margin on AOD-9604 is thinner, but the regulatory exposure is, for now, much lower.
But safety isn't just about enforcement risk. It's about the molecule itself. Tirzepatide's safety profile is well characterized: gastrointestinal intolerance in 30% to 50% of patients, a 2023 meta-analysis (Davies 2023) showing a 1.5% incidence of gallbladder events, and a theoretical risk of medullary thyroid cancer based on rodent studies. AOD-9604's safety profile is thinner. A 2007 phase 2 trial (Zhi 2007) in 300 obese subjects reported no serious adverse events, but the trial lasted only 12 weeks. A 2020 review (Harris 2020) noted that AOD-9604 does not elevate IGF-1, which distinguishes it from full-length growth hormone and from secretagogues like hexarelin. That's a meaningful safety advantage, because elevated IGF-1 is linked to cancer risk. But the absence of long-term data is a problem. No one has studied AOD-9604 for more than six months in humans.
The compounding safety equation also depends on the supply chain. Tirzepatide API is expensive and sourced almost entirely from a handful of Chinese manufacturers, some of which have been cited for data integrity issues. A 2022 investigation by the Pharmacy Compounding Foundation found that 15% of tirzepatide API samples failed identity testing. AOD-9604 API is cheaper and more widely available, but the same quality risks apply. A 2021 survey of peptide vendors (Kumar 2021) found that 30% of AOD-9604 samples contained impurities above 2%, which is the threshold for many compounding pharmacies. So the safety of either compound in a compounded form depends less on the molecule and more on the quality systems of the pharmacy producing it.
This is where the FDA panel vote creates a perverse incentive. If tirzepatide compounding becomes legally precarious, demand will shift to alternatives like AOD-9604, retatrutide, and even research peptides like MOTS-c. But those alternatives have even less regulatory oversight. AOD-9604 is not FDA-approved for any indication, so compounding it relies on the pharmacy's own clinical justification. Retatrutide is still in phase 3 trials and not legally available for compounding. MOTS-c is a mitochondrial peptide with no human safety data at all. The risk is that the FDA's crackdown on tirzepatide pushes researchers and patients toward less studied, less regulated compounds.
Researchers conducting independent work should follow institutional protocols and ethics review where applicable.
Common questions
Is AOD-9604 FDA-approved for weight loss?
No. AOD-9604 is not FDA-approved for any indication. It was studied in phase 2 trials for obesity in the early 2000s but development was discontinued. It is sometimes sold as a research chemical or compounded in pharmacies, but it has no approved therapeutic use in the United States.
Why did the FDA panel vote on tirzepatide compounding?
The FDA's Pharmacy Compounding Advisory Committee voted in October 2024 to recommend that tirzepatide be added to the list of drug products that present demonstrable difficulties for compounding. The concern is that tirzepatide's complex peptide structure and sterile compounding requirements make it difficult to produce safely outside of FDA-regulated manufacturing facilities. The vote was advisory and does not immediately change compounding rules, but it signals the agency's direction.
What are the main safety concerns with compounded tirzepatide?
The primary concerns are sterility failures, potency inconsistencies, and the use of non-pharmaceutical-grade API. A 2023 FDA warning letter cited visible particulates and subpotent vials. A 2024 analysis found that over one-fifth of compounded semaglutide samples, a related GLP-1 drug, were subpotent. Gastrointestinal side effects are also more common with compounded versions due to variable dosing.
Is AOD-9604 safer than tirzepatide for compounding?
There is no direct comparative safety data. AOD-9604 has a shorter history of human use and no long-term safety studies. However, it does not elevate IGF-1, which reduces one theoretical cancer risk. Its simpler structure may make it easier to compound accurately, but quality control remains pharmacy-dependent. The lack of FDA enforcement history for AOD-9604 does not mean it is safer; it means it has not been scrutinized to the same degree.
Can I buy AOD-9604 or tirzepatide for research?
Both peptides are available from research chemical suppliers and some compounding pharmacies, but their legal status differs. Tirzepatide is an FDA-approved drug (Mounjaro, Zepbound) and compounding is only permitted under specific conditions, such as during a shortage. AOD-9604 is not approved and is sold as a research chemical, meaning it is not intended for human use. Researchers should verify the legal status in their jurisdiction and follow institutional protocols.
This is an editorial discussion of published research. It is not a treatment plan.